Revvity’s EUROIMMUN has received CE marking for its Anti-Measles Virus ELISA 2.0 (IgG), the first commercial assay validated for dried blood spot (DBS) sample material, addressing a critical gap in measles diagnostics as global cases continue to rise.

Innovation in sample collection

The newly launched Anti-Measles Virus ELISA 2.0 (IgG) represents a significant advancement in measles diagnostics, particularly for resource-limited settings. This IVDR-compliant solution supports both the diagnosis of measles virus infection and determination of immune status against the virus.

The assay’s key innovation lies in its validation for dried blood spots as a sample material, alongside conventional serum and plasma samples. DBS sampling requires only droplets of capillary blood from a fingertip, deposited onto a paper card, which can then be transported to a laboratory for analysis.

Dr Lars Komorowski, chief scientific officer of EUROIMMUN, explained the significance: “Because there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution.”

Clinical and practical implications

The minimally invasive nature of DBS collection offers substantial advantages in multiple contexts:
• Routine clinical testing where venous blood collection may be challenging
• Research studies requiring simplified sample collection
• Regions with limited medical infrastructure
• Paediatric populations
• Remote or field-based surveillance efforts

With measles cases increasing globally, expanding access to reliable testing supports broader surveillance and prevention strategies. The assay can be processed either manually or automatically using EUROIMMUN’s scalable solutions for DBS processing and ELISA.

Technical specifications

The Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with DBS validation. This approach eliminates the need for laboratories to perform in-house validation of DBS samples.

About the company

Revvity provides health science solutions ranging from discovery to development and diagnosis to cure. The company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics.

For more information, visit: www.revvity.com
Digital issue: Please click here for more information